Lacosamide Hikma Farmacêutica (Portugal) (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilising hyper‑excitable neurons and decreasing the likelihood of repetitive firing that leads to seizures.

The prescribed dose of lacosamide is determined by the treating physician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for lacosamide during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide has a distinct mechanism that enhances slow inactivation, which may offer better tolerability and fewer drug‑interaction concerns. However, therapeutic choice depends on individual patient factors and physician judgment.

The injectable solution should be stored at room temperature, below 25 °C, in its original container. Protect it from excessive moisture and direct sunlight. Do not freeze. Inspect the vial for particulate matter before use.

Lacosamide Hikma is given by intravenous infusion. The rate and duration of infusion are determined by the prescribing clinician, typically administered over a period of 15 minutes to several hours, depending on the clinical protocol.

The most serious adverse events include cardiac arrhythmias such as atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, and emergence of suicidal thoughts. Patients should be monitored for these signs, and treatment should be discontinued if they occur.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and it should be used with caution in individuals with significant cardiac conduction abnormalities, severe renal or hepatic impairment, or those taking interacting medications that could increase toxicity.